News

Charles River Leverages Virtual Control Groups in GLP Studies

WILMINGTON, Mass., October 27, 2026--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.

Yahoo·08:00CRL▲+0.3%

Charles River Laboratories' Virtual Control Group Database And Methodology To Be Used In An Upcoming Good Laboratory Practice-Compliant Study For Ipsen

This collaboration highlights Charles River’s and Ipsen’s dedication and commitment to championing the 3Rs (Replacement, Reduction, and Refinement of animal use in research) while upholding the highest scientific

Benzinga·04:15CRL▲+0.3%

Charles River Laboratories’ Q3 2026 Earnings: What to Expect

Charles River Laboratories has outpaced the broader market, and analysts remain optimistic as its next earnings report approaches.

Yahoo·02:32CRL▲+0.3%

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment

WILMINGTON, Mass., October 22, 2026--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs

Yahoo·16:30CRL▲+0.3%

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused. The research aims to support safer drug development and more informed regulatory decisions.

Yahoo·16:30CRL▲0.3%

Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs

Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today announced a Research

Benzinga·12:36CRL▲+0.3%

Charles River Laboratories International (CRL) Partners With Magellan As Valuation Questions Linger

Charles River Laboratories International (CRL) drew fresh investor attention after announcing a collaboration with Magellan Stem Cells focused on stem cell therapies and regenerative medicine, supported by biologics quality control and cGMP viral testing. For context, Charles River Laboratories International has seen strong momentum build through 2026, with the share price at US$344.87 after a 1-day share price return of 9.33%, a 30-day share price return of 23.60% and a year-to-date share...

Yahoo·10:11

$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today

Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market capitalization of $15.34

Benzinga·14:15CRL▲+0.3%

Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.

Yahoo·11:07CRL▲+0.3%

Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Years

Charles River (NYSE:CRL) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.15%. Currently, Charles River has a market capitalization of $15.44

Benzinga·07:45CRL▲+0.3%

Charles River partners with Magellan Stem Cells on cell therapy

The partnership focuses on biologics quality control as well as viral and release testing under cGMP standards.

Yahoo·06:25CRL▲+0.3%

Healthcare Contract Research Organization (CRO) - Global Strategic Business Report: Secure Share of US$63.3 Billion Market by 2032 as IQVIA, ICON, Charles River, and Syneos Health Accelerate AI Trials

Outsource clinical trials and leverage AI, decentralized models and regulatory expertise to cut costs, accelerate drug development and expand patient access.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Healthcare Contract Research Organization (CRO) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Healthcare Contract Research Organization (CRO) Market to Reach US$63.3 Billion by 2032 The global Healthcare Contract Research Organization (CRO) market, e

Yahoo·04:11CRL▲+0.3%

Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340

Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.

Benzinga·08:24CRL▲+0.3%

Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

WILMINGTON, Mass., October 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r

Yahoo·08:00CRL0.3%

Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions

Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical

Benzinga·04:04CRL▲+0.3%

Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera

Boost ROI with AI-led design, automated high-throughput screening, customizable libraries, local production and diversified sourcing to cut costs and speed development.Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- "Synthetic Antibody Library Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global synthetic antibody library market is experiencing rapid expansion, supported by rising demand for therapeutic antibodies, continued growth in biopharmaceutical research an

Yahoo·10:00CRL▲+0.3%

Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases

Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...

Yahoo·15:06CRL▲+0.3%

Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39

Fintel·03:13CRL▲+0.3%

Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory

Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Animal Model - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp

Yahoo·09:28CRL▲+0.3%

Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today

Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market capitalization of $15.15

Benzinga·07:00

UBS Reinstates Buy on Charles River, Announces $357 Price Target

UBS analyst Kevin Caliendo reinstates Charles River (NYSE:CRL) with a Buy and announces $357 price target.

Benzinga·04:42CRL▲+0.3%

Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery

Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]

Yahoo·12:11CRL▲+0.3%

Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River

Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to

NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs

Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:

Yahoo·07:33CRL▲+0.3%

Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, The Jackson Laboratory, Taconic Biosciences and Crown Bioscience Profiled

Boost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Experimental Animal Model Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experimental Animal Model Market, which is projected to reach USD 1.31 billion in 2026 and expand at a comp

Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec

Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Contract Research Organization Services Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Market research report provides strategic analysis of a sector projected to reach USD 87.43 billion in

Yahoo·09:01CRL▲+0.3%

Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & Parexel

Opportunities include validated AI, cloud safety platforms, real-world evidence, integrated pharmacovigilance, patient-centric reporting and expansion in emerging markets.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Safety Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The global Drug Safety Market research report examines growth trends, regulatory developments, technology adoption, and regional pharmacovigilance priorities. The market is projected t

Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday

Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.

Benzinga·06:01CRL▲+0.3%

Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow

2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.

SeekingAlpha·05:37CRL▲+0.3%

Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%

Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term financial targets

Benzinga·04:08CRL▲+0.3%

Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave

Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to

Yahoo·04:02

Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI

Demand for outsourced pharmacokinetics services is rising, driven by AI, advanced bioanalysis, personalized medicine, biologics and complex global trials.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmacokinetics Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmacokinetics Services was estimated at US$853.5 Million in 2025 and is projected to reach US$1.4 Billion by 2032, growing at a CAGR of 7.8% from 2025 to 2032. Thi

Yahoo·05:55CRL▲+0.3%

Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030

AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Fragment-based Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Fragment-based Drug Discovery was valued at US$977 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of

Yahoo·04:32CRL▲+0.3%

Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI

PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Patient Derived Xenograft / PDX Models - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Patient Derived Xenograft / PDX Models was valued at US$467.5 Million in 2024 and is projected to reach US$1 Billion b

Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter

On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands […]

Yahoo·22:34CRL▲+0.3%

Charles River’s (CRL) New Automation Push Meets Old Margin Problems

On September 8, Charles River Laboratories (NYSE:CRL) said its newly automated cartridge manufacturing suite for Endosafe endotoxin testing had reached full operational capacity in the third quarter, a milestone it had been building toward since the system went fully live in July. The timing matters. Charles River has spent much of 2026 shedding businesses and […]

Yahoo·22:29CRL0.3%

Can Charles River Laboratories International (CRL) Justify Its Valuation On Its Rapid Cell Banking Launch?

Charles River Laboratories International (CRL) just rolled out rapid cell banking programs built around Next-Generation Sequencing and its Pathoquest acquisition, aiming to shorten development timelines for advanced therapies and strengthen quality and regulatory control. For context, Charles River Laboratories International has seen strong momentum build over the past few months, with a 90-day share price return of 52.25% and a 1-year total shareholder return of 79.42%. These figures point...

Yahoo·16:09CRL▲+0.3%

PGNY vs. CRL: Which Stock Is the Better Value Option?

PGNY vs. CRL: Which Stock Is the Better Value Option?

Yahoo·11:40CRL▲0.3%

What Is Charles River Laboratories International (CRL) Signaling With Its Faster Cell Banking Platform?

Charles River Laboratories International (NYSE:CRL) unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools. The platform is designed to shorten biologics and advanced therapy cell bank lead times for biopharma clients while supporting regulatory readiness. Charles River states that the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The new rapid cell banking and release...

Yahoo·05:14CRL▲+0.3%

Charles River Laboratories International (CRL) Stock Fair Value Rises After Analysts Lift Targets

The analyst fair value estimate for Charles River Laboratories International has shifted from US$230.93 to US$282.43, a change of about 22% in the updated work. That move sits against Street commentary that now ranges from targets in the low US$200s to just above US$300. This reflects both renewed optimism around growth execution and ongoing discussion about valuation and timing. As you read on, you will see how this evolving price target story fits into the broader narrative and what signals...

What Charles River Laboratories International (CRL)'s Accelerated, NGS-Enabled Cell Banking Platform Means For Shareholders

Charles River Laboratories International has introduced rapid cell banking programs that shorten cell bank production timelines by about 40% versus the 20‑week industry standard, integrating rapid microbiological methods and CGMP-compliant Next-Generation Sequencing (NGS) to support faster, higher-quality biologic and advanced therapy development. An interesting aspect of this launch is its alignment with Charles River’s Alternative Methods Advancement Project, which aims to cut reliance on...

Yahoo·18:16CRL▲+0.3%

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 3.6% in the afternoon session after the company announced the launch of rapid cell banking programs designed to accelerate release timelines.

Yahoo·18:10CRL0.3%

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

WILMINGTON, Mass., September 17, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehens

Yahoo·08:00CRL▲+0.3%

3 Reasons to Sell CRL and 1 Stock to Buy Instead

What a fantastic six months it’s been for Charles River Laboratories. Shares of the company have skyrocketed 79.5%, hitting $272.74. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Yahoo·11:16CRL▲+0.3%

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·11:30CRL▲+0.3%

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

Yahoo·11:30CRL▲+0.3%

Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25

Fintel·05:35CRL▲+0.3%

Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific

Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The "Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro

Yahoo·07:52CRL▲+0.3%

Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?

Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.

Yahoo·09:43CRL▲+0.3%

Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today

Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22

Benzinga·12:30CRL▲+0.3%

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?

Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Yahoo·10:40CRL▲+0.3%

3 Inflated Stocks We Approach with Caution

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Yahoo·08:18

Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?

Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...

Yahoo·03:09CRL▲+0.3%

Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?

Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...

Yahoo·20:12CRL▲+0.3%

Are Options Traders Betting on a Big Move in Charles River Stock?

Investors need to pay close attention to CRL stock based on the movements in the options market lately.

Yahoo·11:29CRL▲0.3%

Charles River Gains 88.6% in a Year: What's Driving the Rally?

CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.

Yahoo·10:50CRL▲+0.3%